Practice Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Practice Solutions for Addressing Treatment Delays in Black Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Outcomes studies have shown that Black men are 70% more likely to develop prostate cancer, have earlier onset and more aggressive disease, and higher rates of morbidity and mortality compared to White men. But recent studies have found that after adjusting for nonbiological factors such as access to care and standardized treatment, Black men with metastatic disease realize more favorable survival benefits when provided equal access to therapy.
 
While Black men have been underrepresented in clinical trials and less likely to undergo genomic profiling of metastatic prostate cancer, a key opportunity lies with facilitating access to novel therapies, especially for heavily pre-treated patients with metastatic castration resistant prostate cancer (mCRPC). Studies show that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups. 

When considering that the growing number of therapeutic options for prostate cancer already creates challenges for navigating optimal treatment selection and sequencing, finding solutions to mitigate access to novel agents further challenges the implementation of evidence-based medicine into real-world practice.
 
In response, this educational activity has compiled education and practical tools to help you introduce efficiently and effectively bridge these gaps. It also includes downloadable slide decks and discussion guides to initiate meaningful conversations and improve interprofessional care within your team. Drive changes to positively impact care for your patients by ensuring all patients have access to the right therapies at the right time.
 
Educational Partner: Academy for Continued Healthcare Learning (ACHL)

Medium: e-Learning

Commercial Support: Supported by educational grants from Astellas and Pfizer Inc., Bayer HealthCare Pharmaceuticals Inc, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

This program is intended for medical oncologists, urologists, pathologists, nurse practitioners, physician assistants, oncology pharmacists, nurse navigators and other members of the multidisciplinary team who care for patients with prostate cancer.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Introduce strategies to reduce the median time to treatment for diverse patients with mCRPC;
  • Optimally select targeted therapies in the advanced prostate cancer setting considerate of patient- and disease-related factors;
  • Identify patients with mCRPC who may be eligible for a clinical trial;
  • Apply tactics to improve care coordination, access to care, and SDM for Black men with mCRPC.
Additional information
ACGME/ABMS Core Competencies: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
For more information, please contact:
CME Coordinator Contact Name: 
Laurie Navoryta
CME Coordinator Contact Email: 
[email protected]
Summary
Activity opens: 
07/15/2025
Activity expires: 
07/15/2026
FACULTY
Russell Z. Szmulewitz, MD (Chair)
Professor of Medicine
Director, Genitourinary Oncology Program
Associate Director for Clinical Investigation, Comprehensive Cancer Center
Co-Director, High Risk and Advanced Prostate Cancer Clinic
University of Chicago
Chicago, IL
 
Samuel L. Washington III, MD, MAS  (Faculty)
Assistant Professor, Urology
Urologic Oncologist
University of California, San Francisco
San Francisco, CA
 
Meghan Catenacci, BSN, RN, MS (Faculty)
Oncology Nurse Navigator
Hematology/Oncology
University of Chicago Medicine
Chicago, IL
 
Timothy McNichol, LCSW (Faculty)
Genitourinary Outpatient Social Worker
Medical Oncology
University of Chicago Medicine
Chicago, IL
 
Rebecca LaRue, PharmD, BCOP (Peer Reviewer)
Clinical Pharmacy Specialist Hematology/Oncology/Cellular Therapy
Team Lead Hematology/Oncology Pharmacy
Rush University Medical Center
Chicago, IL

Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
The University Of Chicago Pritzker School Of Medicine designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

MIPS logo
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email. 
Registration: To view this activity, visit the ACHL website.
If you are logged in, click on the "Complete Activity" button below!
 
Please login or create an account to proceed.